Diversified Trust Co Makes New Investment in Insulet Co. (NASDAQ:PODD)

Diversified Trust Co purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,782 shares of the medical instruments supplier’s stock, valued at approximately $820,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. Sunbelt Securities Inc. bought a new stake in shares of Insulet in the 1st quarter worth approximately $29,000. Wolff Wiese Magana LLC raised its holdings in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 134 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Insulet in the 4th quarter worth approximately $34,000. Jones Financial Companies Lllp bought a new stake in shares of Insulet in the 4th quarter worth approximately $40,000. Finally, Lindbrook Capital LLC increased its position in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after acquiring an additional 75 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Raymond James dropped their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Barclays dropped their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Canaccord Genuity Group lifted their target price on shares of Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group lifted their target price on shares of Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $239.18.

Insulet Price Performance

Shares of Insulet stock opened at $197.19 on Wednesday. The firm has a fifty day simple moving average of $184.83 and a 200-day simple moving average of $186.20. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $293.64. The stock has a market capitalization of $13.81 billion, a price-to-earnings ratio of 59.75, a PEG ratio of 3.63 and a beta of 1.16.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The business had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. During the same period in the previous year, the company earned $0.23 earnings per share. Insulet’s revenue for the quarter was up 23.3% on a year-over-year basis. On average, sell-side analysts expect that Insulet Co. will post 3.11 earnings per share for the current year.

Insider Transactions at Insulet

In related news, SVP Mark N. Field sold 1,500 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares in the company, valued at approximately $2,574,485. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the completion of the transaction, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares of the company’s stock, valued at $2,574,485. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.